bio

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional…

2 weeks ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a…

3 weeks ago

Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech

Specializing in enzymes and fermentation, the biotech company will transform the expansion of Kemin's global enzyme production capabilities DES MOINES, Iowa…

3 weeks ago

LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly

NORWALK, Conn., Sept. 23, 2025 /PRNewswire/ -- Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio,…

3 weeks ago

Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green…

1 month ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…

1 month ago

Tevogen Recognized in BINJEs BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today…

2 months ago

Life Biosciences Announces Research Collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to Expand Pipeline of Cellular Rejuvenation Therapies

Collaboration in Singapore aims to further expand the broad potential of Life Bio’s Partial Epigenetic Reprogramming Platform as part of…

3 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

4 months ago